TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27872072

Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 36
Study: 27872115

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT) performed at 18-20 gestational weeks (early OGTT)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT) performed at 24-28 gestational weeks (regular OGTT)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Early OGTT
Number of subjects: 570
Study: 27872130

Group type: EXPERIMENTAL
Intervention: Ipatasertib (GDC-0068), 200 mg daily or more
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipatasertib (GDC-0068)
Number of subjects: 0
Study: 27872236

Group type: EXPERIMENTAL
Intervention: RO6836191 (single doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RO6836191 (repeat-dose toxicity studies)
Number of subjects: 0
Study: 27872611

Group type: EXPERIMENTAL
Intervention: Whole Grain Oat Granola (WGO)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Non-Whole Grain (NWG) breakfast cereals
Number of subjects: 32
Study: 27873237

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical patients (control)
Number of subjects: 0
Study: 27873291

Group type: EXPERIMENTAL
Intervention: High SPD (above the 85th percentile)
Number of subjects: 758
Study: 27875056

Group type: EXPERIMENTAL
Intervention: NSAIDs (both OTC and prescribed)
Number of subjects: 2767

Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 2767
Study: 27875368

Group type: EXPERIMENTAL
Intervention: Ultrasound guided radiofrequency neurotomy of the superior medial, superior lateral and inferior medial genicular nerves
Number of subjects: 25
Study: 27875488

Group type: EXPERIMENTAL
Intervention: IV esomeprazole, infusion duration of 10 to 30 minutes
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Oral esomeprazole, pediatric doses based on population pharmacokinetic modeling
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Exposure-response analysis for intragastric pH
Number of subjects: 167

Group type: COMPARATOR
Intervention: Mucosal healing assessed by endoscopy
Number of subjects: 167
Study: 27875519

Group type: EXPERIMENTAL
Intervention: Somatostatin receptor expression measured on circulating tumour cells (CTCs) using CellSearch and immunohistochemistry on matched tissue samples.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flow cytometry analysis of SSTR expression.
Number of subjects: 0
Study: 27875999

Group type: EXPERIMENTAL
Intervention: Initial HBB training
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: Pre-refresher training evaluation
Number of subjects: 835
Study: 27876675

Group type: EXPERIMENTAL
Intervention: Trametinib plus docetaxel (2.0 mg once daily, 75 mg/m2 docetaxel)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Trametinib plus pemetrexed
Number of subjects: 89
Study: 27878356

Group type: EXPERIMENTAL
Intervention: Intravenous triapine (48-96 mg/m) in combination with cisplatin chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous triapine (48-96 mg/m)
Number of subjects: 0
Study: 27878474

Group type: EXPERIMENTAL
Intervention: Single dose of warfarin
Number of subjects: 150
Study: 27878567

Group type: EXPERIMENTAL
Intervention: Peficitinib 150 mg daily for 9 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg on days 1 and 10
Number of subjects: 24
Study: 27878619

Group type: EXPERIMENTAL
Intervention: Activated carbon applied locally into the rectum twice daily for 8 weeks
Number of subjects: 28
Study: 27878892

Group type: EXPERIMENTAL
Intervention: SIGLEC9 polymorphisms (specifically the G allele of rs2075803 and rs2075803 G/rs2258983 A haplotype)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Myeloid cell line expressing the Siglec-9 variant corresponding to GA haplotype
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: SIGLEC9 rs2075803 G/rs2258983 A haplotype
Number of subjects: 135
Study: 27878906

Group type: EXPERIMENTAL
Intervention: simeprevir 150 mg, daclatasvir 60 mg and sofosbuvir 400 mg, once daily for 12 weeks
Number of subjects: 40
Study: 27879486

Group type: EXPERIMENTAL
Intervention: Tenofovir administered from week 28 of pregnancy until delivery
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Tenofovir plus serovaccination to newborns
Number of subjects: 31
Study: 27879972

Group type: EXPERIMENTAL
Intervention: REGN2810 (anti-PD-1 monoclonal antibody)
Number of subjects: 2
Study: 27881039

Group type: EXPERIMENTAL
Intervention: Fludarabine, cyclophosphamide, and lenalidomide (starting dose 2.5 mg, maximum tolerated dose 5 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fludarabine, cyclophosphamide, and lenalidomide (FC regimen)
Number of subjects: 40
Study: 27881132

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 μg
Number of subjects: 3345

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 200 μg
Number of subjects: 3345

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3345
Study: 27881360

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 800
Study: 27881568

Group type: EXPERIMENTAL
Intervention: Type 2 myocardial infarction (T2MI)
Number of subjects: 1251

Group type: EXPERIMENTAL
Intervention: T2MI
Number of subjects: 1251

Group type: EXPERIMENTAL
Intervention: Incident diagnosis of T2MI
Number of subjects: 1251
Study: 27881569

Group type: EXPERIMENTAL
Intervention: Extended-duration oral betrixaban (80 mg once daily for 35-42 days)
Number of subjects: 7513

Group type: COMPARATOR
Intervention: Standard-dose subcutaneous enoxaparin (40 mg once daily for 10±4 days)
Number of subjects: 7513
Study: 27881690

Group type: EXPERIMENTAL
Intervention: Ready-to-use food (RUF) protocols with Plumpy Nut and Plumpy Sup supplied every 2 weeks, prescribed by weight
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ready-to-use food (RUF) protocols
Number of subjects: 43
Study: 27882104

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell (MSC) infusion derived from human umbilical cord
Number of subjects: 34
Study: 27882418

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) guidelines compliance
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Postoperative discharge criteria fulfillment
Number of subjects: 168

Group type: COMPARATOR
Intervention: Postoperative complications
Number of subjects: 168

Group type: COMPARATOR
Intervention: Length of hospitalization
Number of subjects: 168

Group type: COMPARATOR
Intervention: Readmission rate
Number of subjects: 168
Study: 27883002

Group type: EXPERIMENTAL
Intervention: ELLIPTA
Number of subjects: 0
Study: 27883166

Group type: EXPERIMENTAL
Intervention: Low-dose rapamycin (0.5mg, 1.0mg, 2mg daily for 12 weeks)
Number of subjects: 13
Study: 27883239

Group type: EXPERIMENTAL
Intervention: Omalizumab (individualized dosing)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Omalizumab (elevated dose)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Omalizumab (normal dose)
Number of subjects: 23
Study: 27883297

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (maintenance dose)
Number of subjects: 93
Study: 27884107

Group type: EXPERIMENTAL
Intervention: Surgery under general anesthesia
Number of subjects: 70

Group type: COMPARATOR
Intervention: Matched nonsurgical controls
Number of subjects: 70
Study: 27884134

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a plus ribavirin
Number of subjects: 81

Group type: COMPARATOR
Intervention: Peginterferon alpha-2b plus ribavirin
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 81
Study: 27884137

Group type: COMPARATOR
Intervention: Preventive sick leave intervention by the general practitioner (GP) using the Work Stress Questionnaire (WSQ), GP training in the use of WSQ, GP feedback at consultation, and finding suitable preventive measures.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (control group).
Number of subjects: 0
Study: 27884140

Group type: EXPERIMENTAL
Intervention: Cisplatin (on day 1, every 3 weeks) and cetuximab (on day 1, weekly), in combination with oral valproic acid (VPA) given daily from day -14 with a target serum level of 50-100 μg/ml.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cisplatin and cetuximab with valproic acid (VPA)
Number of subjects: 60
Study: 27884157

Group type: EXPERIMENTAL
Intervention: OptiScanner® CGM device
Number of subjects: 88

Group type: COMPARATOR
Intervention: Reference method (standard reference method for BG measurement)
Number of subjects: 88
Study: 27884211

Group type: EXPERIMENTAL
Intervention: Pre-operative plasma glutamine level
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Post-operative plasma glutamine level
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pre-operative plasma glutamine levels
Number of subjects: 90
Study: 27884313

Group type: EXPERIMENTAL
Intervention: Normal BMI (18.5-22.9)
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Overweight (23.0-27.4)
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Obese (27.5 and over)
Number of subjects: 1078
Study: 27884766

Group type: EXPERIMENTAL
Intervention: GSK2256294 (10 μM)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: GSK2256294 (18 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Bradykinin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 23

Group type: COMPARATOR
Intervention: EET/dihydroxyepoxyeicosatrienoic acid ratio
Number of subjects: 23
Study: 27884941

Group type: EXPERIMENTAL
Intervention: Physical performance tests and sociodemographic surveys
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Multivariate prediction models
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Validation of a multivariate model
Number of subjects: 480
Study: 27885499

Group type: EXPERIMENTAL
Intervention: Doxazosin 8 mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 61
Study: 27885830

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 0
Study: 27886569

Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 240
Study: 27887595

Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship program of Chinese MOH
Number of subjects: 978
Study: 27887632

Group type: COMPARATOR
Intervention: Sorafenib (antiangiogenic drug)
Number of subjects: 0
Study: 27887644

Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (cART)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Uninfected controls from the Copenhagen General Population Study (CGPS)
Number of subjects: 1500
Study: 27887654

Group type: EXPERIMENTAL
Intervention: Meeting the 24-h movement recommendations (all three behaviors)
Number of subjects: 6128

Group type: EXPERIMENTAL
Intervention: Including the MVPA recommendation in the analysis
Number of subjects: 6128
Study: 27887660

Group type: EXPERIMENTAL
Intervention: Co-infusion of haplo-identical donor-derived CD19-directed CAR-T cells and mobilized peripheral blood stem cells (PBSC)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Co-infusion of haplo-identical donor-derived CD19-directed CAR-T cells and mobilized PBSC
Number of subjects: 1
Study: 27887718

Group type: EXPERIMENTAL
Intervention: Trak Male Fertility Testing System
Number of subjects: 239
Study: 27887774

Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 0
Study: 27888172

Group type: EXPERIMENTAL
Intervention: Persistent inactive disease (t2)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Changing from very high disease activity to inactive disease (t3)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Persistent high disease activity (t4)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Persistent very high disease activity (t5)
Number of subjects: 370
Study: 27888609

Group type: EXPERIMENTAL
Intervention: Lorcaserin
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 27888649

Group type: EXPERIMENTAL
Intervention: Balloon sinus dilation
Number of subjects: 50
Study: 27888762

Group type: EXPERIMENTAL
Intervention: Marine omega-3 eicosapentaenoic acid (EPA)
Number of subjects: 100
Study: 27889300

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily combined with methotrexate
Number of subjects: 2136

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 2136

Group type: COMPARATOR
Intervention: Other active treatments
Number of subjects: 2136
Study: 27890073

Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice per day
Number of subjects: 191

Group type: COMPARATOR
Intervention: Imatinib 600 mg once per day
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice per day (excluding crossover responses)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Imatinib 600 mg once per day (excluding crossover responses)
Number of subjects: 191
Study: 27890471

Group type: EXPERIMENTAL
Intervention: Riociguat (0.5-2.5 mg TID) during a 10-week titration phase and a 14-week maintenance phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Riociguat (0.5-2.5 mg TID)
Number of subjects: 0
Study: 27890526

Group type: EXPERIMENTAL
Intervention: Paclitaxel eluting balloon (PEB) angioplasty
Number of subjects: 53
Study: 27890712

Group type: EXPERIMENTAL
Intervention: Quantitative CT measures of BA ratio
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Quantitative CT measures of wall thickness (WT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Quantitative CT measures of wall area percent (WA%)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Bronchiectatic airways
Number of subjects: 42
Study: 27890936

Group type: EXPERIMENTAL
Intervention: Imatinib treatment cessation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Functional characterization of NK and T cells
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison with T and B cells
Number of subjects: 100
Study: 27891160

Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment
Number of subjects: 288
Study: 27891190

Group type: EXPERIMENTAL
Intervention: Cell-free DNA promoter hypermethylation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylation-specific PCR of a 28 gene panel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 27891230

Group type: EXPERIMENTAL
Intervention: Prucalopride 0.02 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prucalopride 0.04 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prucalopride 0.06 mg/kg
Number of subjects: 0
Study: 27891264

Group type: EXPERIMENTAL
Intervention: Gene-activated bone substitute composed of collagen-hydroxyapatite scaffold and plasmid DNA encoding vascular endothelial growth factor
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Gene-activated bone substitute
Number of subjects: 1
Study: 27893465

Group type: EXPERIMENTAL
Intervention: Typhoid vaccine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cantharidin-induced skin blisters
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: D-resolvin pathway
Number of subjects: 64
Study: 27894069

Group type: EXPERIMENTAL
Intervention: Left Atrial (LA) size measurements
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Quantitative measurements of LA and diastolic function
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Identification of asymptomatic patients with increased hemodynamic burden
Number of subjects: 39
Study: 27895003

Group type: EXPERIMENTAL
Intervention: High protein supplementation (1.2 g/kg IBW per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard protein supplementation (0.8 g/kg IBW per day)
Number of subjects: 0
Study: 27895016

Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir (LPV/r) prophylaxis
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Lamivudine (3TC) prophylaxis
Number of subjects: 161
Study: 27895026

Group type: EXPERIMENTAL
Intervention: N-Terminal Pro-Brain Natriuretic Peptide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brain Natriuretic Peptide
Number of subjects: 0
Study: 27895066

Group type: EXPERIMENTAL
Intervention: Health status assessments and longitudinal follow-up examinations
Number of subjects: 600
Study: 27895069

Group type: EXPERIMENTAL
Intervention: Cognitive function assessment using a neuropsychological battery at baseline.
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Cognitive function assessment with a focus on memory.
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Cognitive function assessment with a focus on executive function.
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Cognitive function assessment with a focus on attention.
Number of subjects: 309
Study: 27895279

Group type: EXPERIMENTAL
Intervention: Immunoglobulin G (IgG) responses to malaria
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27895500

Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Number of subjects: 249

Group type: COMPARATOR
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 249
Study: 27895549

Group type: EXPERIMENTAL
Intervention: Cochlear Implantation
Number of subjects: 0
Study: 27896243

Group type: EXPERIMENTAL
Intervention: Tivantinib (ARQ-197)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27896545

Group type: EXPERIMENTAL
Intervention: Pasireotide long-acting release 40 mg administered intramuscularly every 28 days
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pasireotide long-acting release for ≥3 months (n=42)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pasireotide long-acting release for ≥15 months (n=10)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pasireotide long-acting release
Number of subjects: 44
Study: 27896822

Group type: EXPERIMENTAL
Intervention: Simeprevir 150 mg once-daily plus Sofosbuvir 400 mg once-daily for 12 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Simeprevir plus Sofosbuvir treatment
Number of subjects: 40
Study: 27898284

Group type: EXPERIMENTAL
Intervention: VLDL-TG storage in muscle tissue
Number of subjects: 23

Group type: COMPARATOR
Intervention: LPL activity
Number of subjects: 23

Group type: COMPARATOR
Intervention: LPL activity in abdominal fat
Number of subjects: 23
Study: 27898605

Group type: EXPERIMENTAL
Intervention: ABI surgery
Number of subjects: 10
Study: 27898687

Group type: EXPERIMENTAL
Intervention: Exposure to young children
Number of subjects: 1646

Group type: EXPERIMENTAL
Intervention: Older ages
Number of subjects: 1646

Group type: EXPERIMENTAL
Intervention: Younger ages
Number of subjects: 1646
Study: 27898728

Group type: EXPERIMENTAL
Intervention: COPD patients with NTHi infection (NTHi+ve)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: NTHi+ve COPD patients
Number of subjects: 32

Group type: COMPARATOR
Intervention: NTHi-negative COPD patients
Number of subjects: 32
Study: 27899340

Group type: EXPERIMENTAL
Intervention: CopeSmart mobile phone app
Number of subjects: 208
Study: 27899339

Group type: EXPERIMENTAL
Intervention: Facebook-delivered health communication intervention targeting mothers
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Attention-control Facebook private group
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 2000
Study: 27899488

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 27899490

Group type: EXPERIMENTAL
Intervention: GoCARB System for carbohydrate estimation
Number of subjects: 0
Study: 27899499

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients (n = 188)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients (n = 163)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Both diabetes types
Number of subjects: 391

Group type: COMPARATOR
Intervention: Control subjects (n = 80 total, 40 each group)
Number of subjects: 391
Study: 27899752

Group type: EXPERIMENTAL
Intervention: PFO prevalence in cryptogenic stroke patients (ASCO 0 and 3)
Number of subjects: 3497

Group type: EXPERIMENTAL
Intervention: PFO prevalence in ASCO 3 patients
Number of subjects: 3497

Group type: EXPERIMENTAL
Intervention: PFO prevalence in ASCO 0 patients
Number of subjects: 3497

Group type: EXPERIMENTAL
Intervention: PFO prevalence in ASCO 0- patients
Number of subjects: 3497

Group type: EXPERIMENTAL
Intervention: PFO prevalence in ASCO 0+ patients
Number of subjects: 3497
Study: 27899756

Group type: EXPERIMENTAL
Intervention: Nonspecific coagulation tests (international normalized ratio, activated partial thromboplastin time, and thrombin time)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Specific coagulation tests (antifactor Xa tests, hemoclot assay)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Nonspecific coagulation tests (activated partial thromboplastin time and international normalized ratio)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: NOAC treatment
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Nonspecific coagulation tests
Number of subjects: 290
Study: 27900127

Group type: EXPERIMENTAL
Intervention: Lung cancer surgery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Non-exercising patients
Number of subjects: 70
Study: 27900144

Group type: EXPERIMENTAL
Intervention: Ankle-brachial index (ABI) at rest in low-risk asymptomatic middle-aged trained adults
Number of subjects: 674

Group type: COMPARATOR
Intervention: Ankle-brachial index (ABI) in sedentary individuals (SED)
Number of subjects: 674
Study: 27900169

Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise and counselling for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Counselling alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-treatment control group
Number of subjects: 0
Study: 27900175

Group type: EXPERIMENTAL
Intervention: Preventive free fall acrobatics (intervention jump) involving reducing parachute deployment airspeed and positioning the body head high.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control jump (no acrobatic elements).
Number of subjects: 0
Study: 27900177

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Baseline control
Number of subjects: 20